Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
1 clinical trials · Condition
◉ Watch Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
| Record | Firm | Date |
|---|---|---|
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (NCT05652686) | Phanes Therapeutics | 2023-09-05 |
Track Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) automatically
Every clearance here is in the API, with alerts when new ones post.